Key Takeaways
- Emcure's strong international expansion fuels revenue growth.
- CIFC's diversified lending mix strengthens risk profile.
- Both stocks target double‑digit earnings growth in FY27.
- Projected CAGRs support a positive outlook for FY26‑FY28.
Market Outlook for the Holiday‑Shortened Week
The Bombay Stock Exchange will open on September 18 after a brief pause for the Independence Day celebrations. Motilal Oswal’s Wealth Management Research Desk identified two names that have emerged as the most attractive plays for this week: Emcure Pharmaceuticals and Cholamandalam Investment & Finance Company Ltd (CIFC). Both companies show robust financial health, favourable valuation multiples and clear growth strategies that align with the current market sentiment.
Emcure Pharmaceuticals – Strengthening Global Presence
Emcure has built a solid reputation in India but its strategic focus has steadily expanded beyond domestic borders. The company’s pipeline is heavily weighted towards specialty formulations in the anti‑infective, anti‑inflammatory and oncology segments, which have higher price points and lower competition than generic Indian brands.
In the first quarter of FY27, Emcure recorded a 22.8% year‑over‑year rise in revenue, reaching ₹25.8 billion. EBITDA climbed by 25.8% to ₹5.1 billion, and adjusted PAT surged by a remarkable 34% to ₹2.9 billion. These gains are largely attributable to a surge in international sales, which now account for a larger share of the top line than ever before.
While gross margin contracted by 340 basis points to 58.4% YoY, this dip can be attributed to higher cost of goods sold in the export markets and pricing pressures from competitors. Nevertheless, the domestic business grew at a modest 10% YoY, underscoring that international growth remains the key driver for the company.
Future Outlook and Growth Drivers
Management forecasts revenue growth in the low to mid‑teens for FY27, with an EBITDA margin expansion of 70–100 basis points. Emcure plans to continue its international expansion, launch new products, and strengthen domestic execution to sustain earnings momentum.
Motilal Oswal projects a revenue CAGR of 15%, EBITDA CAGR of 21% and PAT CAGR of 25% for FY26–FY28, reflecting confidence in Emcure’s ability to maintain growth in both markets.
Cholamandalam Investment & Finance Company – Diversifying Beyond Vehicle Finance
Cholamandalam Investment (CIFC) has been transitioning from a niche vehicle‑finance company into a diversified lending platform. This shift is expected to unlock new growth avenues and enhance earnings resilience.
Mortgage lending has become a major growth engine, complementing the traditional vehicle‑finance franchise. In addition, the company is expanding into gold loans, consumer finance and micro‑small‑medium enterprise (MSME) lending, which offer higher yields and lower risk concentration.
Margins remain stable even as funding costs rise. Net interest margin (NIM) is projected to be 7.3% in FY27 and 7.1% in FY28, reflecting a cushion from a favourable funding mix and the increasing share of higher‑yielding businesses. Operating leverage is expected to improve, with Return on Assets (RoA) rising from 2.3% in FY26 to 2.7% in FY27 and FY28, while Return on Equity (RoE) is expected to hover around 20%.
Read also: Bank of Russia flags stablecoins as financial market risk
Projected Growth and Valuation
The analysts forecast a compounded annual growth rate of around 21% in assets under management (AUM) and 27% in PAT over FY26–FY28. The stock is currently trading at roughly 4.1× FY27 projected price‑to‑book value, a premium over peers that is justified by its superior growth prospects and diversified revenue streams.
Contextualizing the Picks for Indian Investors
Both Emcure and CIFC represent two distinct yet complementary sectors that are thriving in India’s current macro‑environment. The pharmaceutical sector has benefited from a steady rise in domestic demand for specialty drugs and a growing acceptance of Indian generics in overseas markets. Meanwhile, the financial services sector continues to see robust growth in retail lending, especially in the mortgage and consumer loan space, buoyed by supportive regulatory reforms and an improving credit appetite among the middle class.
For investors in India, buying into these companies offers a blend of domestic exposure and international diversification. Emcure’s focus on high‑margin specialty drugs can provide a hedge against commodity price swings, while CIFC’s multi‑line lending model can offer stable income from diversified sources of interest earnings.
What to Watch Next?
- Keep an eye on Emcure’s quarterly earnings for any updates on international pipeline performance and potential new product approvals in the U.S. and EU markets.
- Monitor CIFC’s mortgage origination volumes and interest rate environment, as changes in the repo rate could impact NIM and loan growth.
- Stay updated on regulatory developments in the banking and pharmaceutical sectors that could affect funding costs or export incentives.
Investment Takeaways for the Indian Market
- Emcure demonstrates strong earnings growth driven by expanding international markets.
- CIFC is broadening its lending mix, reducing concentration risk.
- Both companies target double‑digit growth in FY27 with solid margin expansion.
- Projected CAGRs suggest a favourable outlook for FY26‑FY28.
Conclusion
For the holiday‑shortened trading week starting September 18, 2026, Emcure Pharmaceuticals and Cholamandalam Investment & Finance Company present compelling buy cases. Their growth stories—one rooted in global pharma expansion and the other in diversification of lending platforms—align with current market dynamics and investor appetite for resilient, high‑growth equities.
Frequently Asked Questions
What are the key growth drivers for Emcure Pharmaceuticals in FY27?
Emcure's growth is driven by expanding international sales, especially in Europe and Canada, along with a strong pipeline of niche therapeutic products and improved commercial network execution.
How is Cholamandalam Investment diversifying its lending portfolio?
Cholamandalam is adding mortgages, gold loans, consumer finance and MSME lending to its traditional vehicle‑finance franchise, creating higher‑yielding and less concentrated earnings streams.
Why might Indian investors consider these stocks during a holiday‑shortened week?
The stocks offer robust fundamentals, favourable valuations, and clear growth plans that align with current market sentiment, making them attractive plays even when market days are limited.
